Thyrocare Technologies Ltd

Thyrocare Technologies Employee Stock Options

Thyrocare Technologies Limited has granted 1,92,000 employee stock options to eligible employees under the company's approved stock option scheme.

Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr

Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.

Value

₹141.4 Cr

Execution

On or before November 30, 2026

Thyrocare Technologies Share Pledge

API Holdings, successor to promoter Docon, released a full pledge over 7.95 crore Thyrocare shares after NCD redemption. No Docon shares remain encumbered.

Thyrocare Technologies Acquisition

API Holdings Limited reported an exempt acquisition of 8.12 crore shares (51.02%) of Thyrocare Technologies Limited, pursuant to the amalgamation of Docon Technologies Private Limited.

Thyrocare Technologies Promoter Buying (Off-Market)

API Holdings acquired 8,12,00,000 shares (51.02%) of Thyrocare Technologies via a NCLT-approved scheme of amalgamation. The transfer resulted from the merger of Docon Technologies into API Holdings.

Promoter stake change

+51.02%

Thyrocare Technologies Earnings Call Transcript: Key Takeaways

Thyrocare Q1 FY27: Consolidated revenue grew 24.3% YoY to INR 240 Cr, EBITDA margin expanded to 32.2%. Strategy shifts toward specialty diagnostics.

Call

Guides 18% growth

Thyrocare Technologies Investor Presentation: Key Takeaways

Thyrocare delivered strong Q1 FY27 results with 24% YoY consolidated revenue growth and 34% YoY PAT growth, driven by pathology network expansion and high-value specialty test launches.

Call

Guides 20% growth

Thyrocare Technologies Q1 FY27 Results: Net Profit ₹51.3 Cr, Up 33.9% YoY

Thyrocare Technologies Ltd reported revenue from operations of ₹240 Cr (+24.4% YoY) and net profit of ₹51.3 Cr (+33.9% YoY) for Q1 FY27.

Key figure

Net profit ₹51.3 Cr · +33.9% YoY